Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ESEsperion Therapeutics, Inc. logo

Esperion Therapeutics, Inc. (ESPR)

NASDAQ Global Market · Currency in USD
$3.18 ▲ +0.00 (+0.00%)
At close: Jul 13, 4:00 PM ET. Market closed.

Summary

Previous Close
$3.18
Open
$3.18
Day's Range
$3.18 – $3.18
52 Week Range
$1.13 – $4.18
Volume
0
Avg. Volume
14,974,604
Market Cap
$661.15M
Beta (5Y Monthly)
1.06
PE Ratio (TTM)
--
EPS (TTM)
-$0.03
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$3.19

Profile: Esperion Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
294
CEO
Sheldon L. Koenig

Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program.

Earnings

DateEst.Actual
May 8, 2026-$0.04-$0.10Miss
Mar 10, 2026$0.23$0.22Miss
Nov 6, 2025-$0.09-$0.16Miss
Aug 5, 2025-$0.17-$0.02Beat
May 6, 2025-$0.18-$0.21Miss
Mar 4, 2025-$0.14-$0.10Beat

Analyst view

Consensus price target
$3.19 ▲ +0.3%
Range $3.16 – $3.28
Rating: Hold
Buy 32% · Hold 60% · Sell 8%

Get free alerts on ESPR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.